Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy

(2021) Jochen Buechner et al.   Blood Advances

Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature

(2021) Ajay Major et al.   LEUKEMIA & LYMPHOMA

Neurotoxicity Biology and Management

(2021) Husain Danish et al.   CANCER JOURNAL

Disparities in the use of checkpoint inhibitors and CAR T-cell therapy: A systematic review.

(2021) Devika R. Jutagir et al.   JOURNAL OF CLINICAL ONCOLOGY

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

(2021) John E Levine et al.   Journal for ImmunoTherapy of Cancer

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

(2020) Max Topp et al.   BLOOD

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

(2020) Nirali N. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)

(2020) Robert David Sandler et al.   Frontiers in Immunology

Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes

(2020) Noa G Holtzman et al.   NEURO-ONCOLOGY

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

(2020) Kitsada Wudhikarn et al.   Blood Cancer Journal

Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome

(2020) Nirav N. Shah et al.   Blood Advances

Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma

(2020) Paolo Strati et al.   Blood Advances

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy

(2020) Jing Pan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Cytopenias after Chimeric Antigen Receptor T-Cells (CAR-T) Infusion; Patterns and Outcomes

(2019) Andrew Shaefer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Toxicities of CD19 CAR-T cell immunotherapy

(2019) Alexandre V. Hirayama et al.   AMERICAN JOURNAL OF HEMATOLOGY

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

(2019) Paul La Rosée et al.   BLOOD

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

(2019) Ana Cordeiro et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy

(2019) Hamza Hashmi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies

(2019) Ying Wang et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

(2019) Ibrahim Yakoub-Agha et al.   HAEMATOLOGICA

CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy

(2019) Delong Liu   Journal of Hematology & Oncology

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

(2019) Rebecca A. Gardner et al.   BLOOD

Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)

(2019) George R. Nahas et al.   LEUKEMIA & LYMPHOMA

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

(2018) Robert Q. Le et al.   ONCOLOGIST

ASBMT Pharmacy Special Interest Group Survey on CAR T Cell Therapy Administrative, Logistical and Toxicity Management Practices in the United States

(2018) Zahra Mahmoudjafari et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

(2018) Kris M. Mahadeo et al.   Nature Reviews Clinical Oncology

Clinical Utilization of Chimeric Antigen Receptors T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation

(2018) Ankit J. Kansagra et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

(2018) Noelle Frey et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline

(2017) Timothy Gilligan et al.   JOURNAL OF CLINICAL ONCOLOGY

Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Betty R. Ferrell et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

(2017) Laura C. Cappelli et al.   ARTHRITIS CARE & RESEARCH

Cornell Assessment of Pediatric Delirium

(2013) Chani Traube et al.   CRITICAL CARE MEDICINE

Etoposide Selectively Ablates Activated T Cells To Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis

(2013) T. S. Johnson et al.   JOURNAL OF IMMUNOLOGY

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability

(2011) Richard N Shiffman et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION